Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating the Role of mRNA Translation Inhibitors in Combination Therapies for Triple-Negative Breast Cancer

FY 2023-24

Summary
Breast cancer is the most frequently diagnosed type of cancer in women and the second leading cause of cancer-related mortality worldwide. Many breast cancer types have well-characterized molecular markers that act as drug targets for treatment. However, triple-negative breast cancer (TNBC) poses significant challenges for drug development as it lacks the three well-established targets. In fact, TNBC is one of the most aggressive and heterogeneous breast cancer subtypes, leading to a poor prognosis. Due to its heterogeneity, the most promising approach to developing effective treatments is the use of combination therapies which involve the use of more than one drug to minimize drug resistance. One possible strategy in treating TNBC is inhibiting protein production. Cancer cells make more proteins to promote abnormal cell growth by enhancing mRNA translation. We previously discovered a highly selective mRNA translation inhibitor, eFT508, which acts in synergy with each of the three FDA-approved CDK4/6 inhibitor drugs (Palbociclib, Abemociclib, and Ribociclib) to reduce breast cancer growth in TNBC cell lines. The objective of this research proposal is to validate the drug combination synergy in different TNBC cell lines and investigate the molecular mechanism underlying this effect. This research proves promising as eFT508 and the CDK4/6 inhibitors are either in phase II clinical trials, or have been approved as chemotherapeutic drugs, and thus could directly lead to better TBNC therapies in the clinic and reduce cancer mortality.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506261
Name
Piric Anastasija A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Role of mRNA Translation Inhibitors in Combination Therapies for Triple-Negative Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biochemical Pathways In Cancer; Cancer Metastasis; Cdk4/6 Inhibitors; Combination Drug Therapies; Drug Screens; Drug Synergy; Eft508; Mrna Translation; Primary Tumour Growth; Triple-Negative Breast Cancer
Abstract
Breast cancer is the most frequently diagnosed type of cancer in women and the second leading cause of cancer-related mortality worldwide. Many breast cancer types have well-characterized molecular markers that act as drug targets for treatment. However, triple-negative breast cancer (TNBC) poses significant challenges for drug development as it lacks the three well-established targets. In fact, TNBC is one of the most aggressive and heterogeneous breast cancer subtypes, leading to a poor prognosis. Due to its heterogeneity, the most promising approach to developing effective treatments is the use of combination therapies which involve the use of more than one drug to minimize drug resistance. One possible strategy in treating TNBC is inhibiting protein production. Cancer cells make more proteins to promote abnormal cell growth by enhancing mRNA translation. We previously discovered a highly selective mRNA translation inhibitor, eFT508, which acts in synergy with each of the three FDA-approved CDK4/6 inhibitor drugs (Palbociclib, Abemociclib, and Ribociclib) to reduce breast cancer growth in TNBC cell lines. The objective of this research proposal is to validate the drug combination synergy in different TNBC cell lines and investigate the molecular mechanism underlying this effect. This research proves promising as eFT508 and the CDK4/6 inhibitors are either in phase II clinical trials, or have been approved as chemotherapeutic drugs, and thus could directly lead to better TBNC therapies in the clinic and reduce cancer mortality.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Piric, Anastasija A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~